Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof

A technology of acetyl hydrazide and pyridine, applied in the field of medicine, can solve problems such as weak alkalinity and difficult purification, and achieve the effect of inhibiting platelet aggregation

Inactive Publication Date: 2008-09-10
TIANJIN INSTITUTE OF PHARMA RESEARCH
View PDF13 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clopidogrel is superior to other drugs in improving the prognosis of ischemic events, with less ADR than ticlopyridine, and better safety than aspirin, but there are reports of TTP and hemolytic uremic syndrome (HUS)
[0005] At the same time, because clopidogrel is an oily substance with a ve

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof
  • Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof
  • Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0059] Example 1:

[0060] α,α-[(4-Fluorophenyl)-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)]acethydrazine (Compound 1)

[0061] In a reaction flask equipped with a stirrer, a condenser and a thermometer, add α,α-[(4-fluorophenyl)-(4,5,6,7-tetrahydrothieno[3,2-c]pyridine- 5-yl)] methyl acetate 19g, anhydrous ethanol 30ml, slowly heated under stirring to dissolve the reaction materials, add 23.3g hydrazine hydrate (80%), continue to heat to reflux, keep the temperature for 6 hours (the plate shows the reaction complete). Then, the solvent was evaporated under reduced pressure. After the evaporation, 50ml of distilled water and 30ml of dichloromethane were added to the residue, stirred well, and the organic layer was separated. The aqueous layer was extracted with 3×30ml of dichloromethane. The organic layers were combined and used anhydrous sulfuric acid. Sodium is fully dried. Dichloromethane was evaporated under reduced pressure to obtain 13.11g of white solid, yield 69%, HPLC:...

Example Embodiment

[0062] Example 2:

[0063] α,α-[(4-chlorophenyl)-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)]-N′-(dimethylmethylene Base) Acetylhydrazine (Compound 2)

[0064] Add α,α-[(4-chlorophenyl)-(4,5,6,7-tetrahydrothieno[3,2-c]pyridine- into a reaction flask equipped with a stirrer, a condenser and a thermometer. 5-yl)] Acetylhydrazine 4g, anhydrous methanol 40ml, start stirring, heat to dissolve. Continue to heat to 40°C, add 0.8 g of acetone dropwise, after the addition, keep the temperature and react for 3 hours. The reaction was stopped and cooled, and a light yellow solid was formed. Filter, wash 3×2ml with anhydrous methanol, and dry to obtain 3.8g of light yellow solid. HPLC: 99.3%, m.p. 169.5-171.1°C, Rf=0.3 (developing solvent: petroleum ether (60-90°C): ethyl acetate=1:1). 1 HNMR (400MHz, DMSO-d6, δppm): 1.64 (s, 3H), 1.86 (s, 3H), 3.30-3.34 (t, 2H), 3.58-3.62 (t, 2H), 4.36 (s, 2H), 5.61 (s, 1H), 7.13-7.77 (m, 6H), 9.99 (br s, 1H).

Example Embodiment

[0065] Example 3:

[0066] α,α-[(3-chlorophenyl)-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)]-N′-[(2-chlorobenzene Yl)methylidene) acetylhydrazine (compound 3)

[0067] The compound was prepared according to the preparation process provided in Example 2, and was composed of α,α-[(3-chlorophenyl)-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl )] Acetylhydrazine reacts with o-chlorobenzaldehyde. HPLC: 99.7%, m.p. 182.6-183.6°C, Rf=0.84 (developing solvent: petroleum ether (60-90°C): ethyl acetate=1:1). 1 H NMR (400MHz, DMSO-d6, δppm): 3.17-3.22 (t, 2H), 3.40-3.51 (t, 2H), 4.72 (s, 2H), 5.46 (s, 1H), 6.88-7.94 (m, 10H), 8.46 (s, 1H), 11.99 (br s, 1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a thieno[3.2-c]pyridine containing acetyl hydrazine derivative or a salt chemically acceptable of the derivative; meanwhile, the invention also discloses a drug combination with the compounds as active-effective components and an application of the same as a medicine for treating platelet aggregation inhibitor, and particularly for preparing, preventing or curing diseases due to the platelet aggregation, such as coronary syndrome, myocardial infarction, myocardial ischemia and cardio-cerebrovascular diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine, more specifically, relates to a compound with anti-platelet aggregation effect and a preparation method thereof. Background technique [0002] Thrombosis can lead to acute myocardial infarction, stroke, pulmonary embolism and other diseases of the heart, brain, and pulmonary circulation, threatening human health and life, and is also a common complication in surgery and a factor of reocclusion after interventional angioplasty. Since platelet aggregation plays an important role in thrombus formation, antiplatelet drugs have become the main drugs for the prevention and treatment of these diseases. Adenosine diphosphate (ADP) is an important agonist for the activation of platelets and the amplification of aggregation effects. By blocking the ADP receptors to inhibit the action of platelets, it has become an important way to prevent pathological thrombosis (coronary heart disease, cerebrovascular di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D495/04A61K31/4365A61P7/02
Inventor 刘默刘登科刘颖徐为人张士俊成碟金丽媛汤立达刘昌孝
Owner TIANJIN INSTITUTE OF PHARMA RESEARCH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap